No Vaccine For Bundibugyo Ebola Rare Strain Surging in DRC, Uganda

Geneva Afrik24 – The World Health Organization has officially declared the rapidly escalating Ebola outbreak in the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern.

The declaration follows confirmation that the surge in deadly hemorrhagic fever is driven by the rare Bundibugyo virus strain, a variant of the pathogen for which no approved vaccines or targeted treatments exist

The global health body was first alerted to an unusual cluster of high-mortality illnesses earlier this month in the Ituri Province of northeastern DRC.

Subsequent laboratory testing by the Institut National de Recherche Biomédicale in Kinshasa confirmed the presence of the Bundibugyo virus.

The situation escalated rapidly over the weekend as health authorities reported hundreds of suspected cases and scores of fatalities across multiple health zones, including Bunia, Rwampara, and Mongbwalu.

Fears of a wider regional crisis were realized when Ugandan health officials confirmed that the virus had crossed international borders, leading to the discovery of two independent cases identified in the Ugandan capital of Kampala among individuals traveling from the DRC, resulting in at least one death and prompting intensive isolation protocols.

BUNDIBUGYO EBOLA OUTBREAK AT A GLANCE (As of May 2026)
+-----------------------------------+-----------------------------------+
| Metric                            | Status / Figure                   |
+-----------------------------------+-----------------------------------+
| Primary Outbreak Epicenter        | Ituri Province, DRC               |
| Countries with Confirmed Cases    | DRC and Uganda                    |
| Estimated Fatality Rate (Past)    | 30% to 50%                        |
| Current Suspected Cases           | Over 246                          |
| Reported Deaths                   | Approximately 100                 |
| Available Approved Vaccine        | None                              |
+-----------------------------------+-----------------------------------+

First discovered in 2007 in the Bundibugyo District of western Uganda, this particular strain of Ebola is one of the least common but remains highly lethal, carrying a historical case fatality rate between 30% and 50%.

Like other Ebola strains, it is a zoonotic virus believed to originate in fruit bats.

It spreads among humans through direct contact with the blood, secretions, or bodily fluids of infected individuals, as well as via contaminated surfaces and unsafe burial practices, our correspondent reports.

What makes this specific emergency extraordinary—and terrifying to frontline medical teams—is the total lack of medical countermeasures.

While the international community successfully deployed the Ervebo vaccine to contain recent outbreaks of the more common Zaire Ebola strain, that vaccine does not offer proven, reliable human protection against the Bundibugyo variant.

Public health officials are openly expressing gravity over the situation as Dr. Jean Kaseya, Director General of the Africa Centres for Disease Control and Prevention, stated that the organization is effectively operating in panic mode due to the absolute lack of medicines and vaccines to support the affected nations.

He stressed that the crisis highlights a critical global equity issue, emphasizing the urgent need for vaccine manufacturing capacity on the African continent.

The response on the ground is severely hampered by regional instability. Ituri Province is a highly mobile commercial hub dealing with ongoing humanitarian crises and insecurity, making contact tracing and infection control exceptionally difficult.

The virus has already taken a toll on local medical infrastructure, with at least four healthcare workers among the dead after treating patients in under-equipped community clinics.

Without a vaccine or specialized antiviral therapeutics, doctors are relying entirely on aggressive supportive care as medical teams are working to save lives by maintaining blood pressure, managing severe dehydration through intravenous fluids, and treating secondary symptoms.

In the meantime, international entities like the Coalition for Epidemic Preparedness Innovations are coordinating with the WHO and regional governments to fast-track candidate vaccines into clinical trials, hoping to deploy experimental options to the frontlines in the coming weeks.